MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status

Acta Neurochirurgica

Volumn 152, Issue 11, 2010, Pages 1827-1834

  Sherman, Jonathan H ^a   Prevedello, Daniel M ^b   Shah, Lubdha ^c   Raghavan, Prashant ^a   Pouratian, Nader ^a   Starke, Robert M ^a   Lopes, M Beatriz S ^d   Shaffrey, Mark E ^a   Schiff, David ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

1p 19q; Co deletion; MRI characteristics; Oligodendroglial tumor

Indexed keywords

ADULT; ARTICLE; ASTROCYTOMA; BRAIN CORTEX; BRAIN REGION; CANCER GRADING; CANCER LOCALIZATION; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TUMOR VOLUME;

ADULT; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; OLIGODENDROGLIOMA;

EID: 78149413481     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-010-0743-1     Document Type: Article

References (36)

1. RR Allison A Schulsinger V Vongtama T Barry KH Shin 1997 Radiation and chemotherapy improve outcome in oligodendroglioma Int J Radiat Oncol Biol Phys 37 399 403 1:STN:280:DyaK2s3it1WlsQ%3D%3D 9069313
2. FG Barker 2nd SM Chang SL Huhn RL Davis PH Gutin MW McDermott CB Wilson MD Prados 1997 Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors Cancer 80 936 941 10.1002/(SICI)1097- 0142(19970901)80:5<936::AID-CNCR15>3.0.CO;2-X 9307194 (Pubitemid 27360923)
3. SH Bigner BK Rasheed R Wiltshire RE McLendon 1999 Morphologic and molecular genetic aspects of oligodendroglial neoplasms Neuro Oncology 1 52 60 1:STN:280:DC%2BD3MrgtFCktw%3D%3D 11550302
4. R Brown MC Zlatescu A Sijben G Roldan J Easaw P Forsyth I Parney R Sevick E Yan D Demetrick D Schiff G Cairncross R Mitchell 2008 The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma Clin Cancer Res 14 2357 2362 1:CAS:528:DC%2BD1cXkvFGmtLc%3D 10.1158/1078-0432.CCR-07-1964 18413825 (Pubitemid 351551068)
5. G Cairncross B Berkey E Shaw R Jenkins B Scheithauer D Brachman J Buckner K Fink L Souhami N Laperierre M Mehta W Curran 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 1:CAS:528:DC%2BD28XntV2hurg%3D 10.1200/JCO.2005.04.3414 16782910 (Pubitemid 46630566)
6. G Cairncross D Macdonald S Ludwin D Lee T Cascino J Buckner D Fulton E Dropcho D Stewart C Schold Jr N Wainman E Eisenhauer 1994 Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 12 2013 2021 1:STN:280:DyaK2M%2Fhs1ylsQ%3D%3D 7931469
7. JG Cairncross K Ueki MC Zlatescu DK Lisle DM Finkelstein RR Hammond JS Silver PC Stark DR Macdonald Y Ino DA Ramsay DN Louis 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 1:STN:280: DyaK1cvkslejug%3D%3D 10.1093/jnci/90.19.1473 9776413
8. L Capelle P Oei H Teoh D Hamilton D Palmer I Low G Campbell 2009 Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works J Med Imaging Radiat Oncol 53 305 309 1:STN:280:DC%2BD1MrgtF2rtQ%3D%3D 10.1111/j.1754-9485.2009.02074.x 19624298
9. GB Caseiras S Chheang J Babb JH Rees N Pecerrelli DJ Tozer C Benton D Zagzag G Johnson AD Waldman HR Jager M Law 2010 Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting Eur J Radiol 73 215 220 10.1016/j.ejrad.2008.11.005 19201123
10. S Cha EA Knopp G Johnson A Litt J Glass ML Gruber S Lu D Zagzag 2000 Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin AJNR Am J Neuroradiol 21 881 890 1:STN:280:DC%2BD3c3ntlSrtA%3D%3D 10815664
11. S Cha T Tihan F Crawford NJ Fischbein S Chang A Bollen SJ Nelson M Prados MS Berger WP Dillon 2005 Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging AJNR Am J Neuroradiol 26 266 273 15709123
12. ERA Cooper 1935 The relation of oligodendrocytes and astrocytes in cerebral tumors J Pathol Bacteriol 41 259 266 10.1002/path.1700410206
13. JM Derlon F Chapon MH Noel S Khouri K Benali MC Petit-Taboue JP Houtteville MH Chajari G Bouvard 2000 Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology Eur J Nucl Med 27 778 787 1:STN:280:DC%2BD3M%2Fot1artA%3D%3D 10.1007/s002590000260 10952489
14. M Eoli L Bissola MG Bruzzone B Pollo C Maccagnano T De Simone L Valletta A Silvani D Bianchessi G Broggi A Boiardi G Finocchiaro 2006 Reclassification of oligoastrocytomas by loss of heterozygosity studies Int J Cancer 119 84 90 1:CAS:528:DC%2BD28Xkslyjt78%3D 10.1002/ijc.21759 16432842
15. LE Ginsberg GN Fuller M Hashmi NE Leeds DF Schomer 1998 The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series Surg Neurol 49 436 440 1:STN:280:DyaK1c7pslSitg%3D%3D 10.1016/S0090-3019(97)00360-1 9537664 (Pubitemid 28153024)
16. T Higa S Maetani K Yoichiro S Nabeshima 2001 TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas Clin Nucl Med 26 119 124 1:STN:280:DC%2BD3M7pt1SgtA%3D%3D 10.1097/00003072-200102000- 00006 11201468 (Pubitemid 32102454)
17. RB Jenkins H Blair KV Ballman C Giannini RM Arusell M Law H Flynn S Passe S Felten PD Brown EG Shaw JC Buckner 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 1:CAS:528:DC%2BD28XhtVyiur3I 10.1158/0008-5472.CAN-06-1796 17047046 (Pubitemid 44672036)
18. MD Jenkinson DG du Plessis TS Smith KA Joyce PC Warnke C Walker 2006 Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features Brain 129 1884 1891 10.1093/brain/awl108 16670176 (Pubitemid 43999419)
19. MD Jenkinson TS Smith AR Brodbelt KA Joyce PC Warnke C Walker 2007 Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype J Magn Reson Imaging 26 1405 1412 10.1002/jmri.21062 17968881 (Pubitemid 350291266)
20. JM Kros T Gorlia MC Kouwenhoven PP Zheng VP Collins D Figarella-Branger F Giangaspero C Giannini K Mokhtari SJ Mork A Paetau G Reifenberger MJ van den Bent 2007 Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome J Neuropathol Exp Neurol 66 545 551 1:CAS:528:DC%2BD2sXnsFKmtLY%3D 10.1097/01.jnen.0000263869.84188.72 17549014 (Pubitemid 46869696)
21. M Law S Oh JS Babb E Wang M Inglese D Zagzag EA Knopp G Johnson 2006 Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response Radiology 238 658 667 10.1148/radiol.2382042180 16396838 (Pubitemid 43134379)
22. M Law S Oh G Johnson JS Babb D Zagzag J Golfinos PJ Kelly 2006 Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas Neurosurgery 58 1099 1107 10.1227/01.NEU. 0000215944.81730.18 16723889 discussion 1099-1107
23. M Levivier D Wikler Jr N Massager P David D Devriendt J Lorenzoni B Pirotte F Desmedt S Simon Jr S Goldman P Van Houtte J Brotchi 2002 The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review J Neurosurg 97 542 550 10.3171/jns.2002.97.3.0542 12507094
24. DN Louis H Ohgaki OD Wiestler WK Cavenee PC Burger A Jouvet BW Scheithauer P Kleihues 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 97 109 10.1007/s00401-007-0243-4 17618441 (Pubitemid 47103521)
25. D Maintz K Fiedler J Koopmann B Rollbrocker S Nechev D Lenartz AP Stangl DN Louis J Schramm OD Wiestler A von Deimling 1997 Molecular genetic evidence for subtypes of oligoastrocytomas J Neuropathol Exp Neurol 56 1098 1104 1:CAS:528:DyaK2sXmvVyku7Y%3D 10.1097/00005072-199710000-00003 9329453
26. ME Mauer MJ Taphoorn A Bottomley C Coens F Efficace M Sanson AA Brandes CC van der Rijt HJ Bernsen M Frenay CC Tijssen D Lacombe MJ van den Bent 2007 Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study J Clin Oncol 25 5731 5737 10.1200/JCO.2007.11.1476 18089867
27. BJ McCarthy JM Propp FG Davis PC Burger 2008 Time trends in oligodendroglial and astrocytic tumor incidence Neuroepidemiology 30 34 44 10.1159/000115440 18259099 (Pubitemid 351311724)
28. JF Megyesi E Kachur DH Lee MC Zlatescu RA Betensky PA Forsyth Y Okada H Sasaki M Mizoguchi DN Louis JG Cairncross 2004 Imaging correlates of molecular signatures in oligodendrogliomas Clin Cancer Res 10 4303 4306 10.1158/1078-0432.CCR-04-0209 15240515 (Pubitemid 38878867)
29. MV Padma S Said M Jacobs DR Hwang K Dunigan M Satter B Christian J Ruppert T Bernstein G Kraus JC Mantil 2003 Prediction of pathology and survival by FDG PET in gliomas J Neurooncol 64 227 237 1:STN:280:DC%2BD3svotVWgsQ%3D%3D 10.1023/A:1025665820001 14558598 (Pubitemid 37203463)
30. N Pouratian A Asthagiri J Jagannathan ME Shaffrey D Schiff 2007 Surgery insight: the role of surgery in the management of low-grade gliomas Nat Clin Pract Neurol 3 628 639 10.1038/ncpneuro0634 17982433 (Pubitemid 350048229)
31. N Pouratian J Gasco JH Sherman ME Shaffrey D Schiff 2007 Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas J Neurooncol 82 281 288 1:CAS:528:DC%2BD2sXlvF2ju7c%3D 10.1007/s11060-006-9280-4 17082887 (Pubitemid 46614391)
32. M Stokkel H Stevens M Taphoorn P Van Rijk 1999 Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera-a pilot study Nucl Med Commun 20 411 417 1:STN:280:DyaK1Mzjt1Kjtg%3D%3D 10.1097/00006231-199905000- 00003 10404525
33. MJ van den Bent JM Kros JJ Heimans LC Pronk CJ van Groeningen HG Krouwer MJ Taphoorn BA Zonnenberg CC Tijssen A Twijnstra CJ Punt W Boogerd 1998 Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group Neurology 51 1140 1145 9781544
34. MJ Vos OS Hoekstra F Barkhof J Berkhof JJ Heimans CJ van Groeningen WP Vandertop BJ Slotman TJ Postma 2003 Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma J Clin Oncol 21 3559 3565 10.1200/JCO.2003.01.001 12913097 (Pubitemid 46594046)
35. C Walker DG du Plessis D Fildes B Haylock D Husband MD Jenkinson KA Joyce J Broome K Kopitski J Prosser T Smith S Vinjamuri PC Warnke 2004 Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component Clin Cancer Res 10 7182 7191 1:CAS:528: DC%2BD2cXpsVKltb8%3D 10.1158/1078-0432.CCR-04-0681 15534091 (Pubitemid 39487704)
36. MC Zlatescu A TehraniYazdi H Sasaki JF Megyesi RA Betensky DN Louis JG Cairncross 2001 Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms Cancer Res 61 6713 6715 1:CAS:528:DC%2BD3MXntFais7Y%3D 11559541